SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alfacell (ACEL)
ACEL 11.54-0.9%Jan 16 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tom DuBois who wrote (1407)6/23/1998 10:05:00 AM
From: Greg Kevorkian  Read Replies (2) of 1533
 
First, all the data that has been generated has to be computer analyzed,
journals entries from the patients on side effects have to be compiled and
analyzed and it all has to be put together. Though the trials are randomized
there is a lot of info that has to be looked and and evaluated.
P1 data and P2 data was good and there is no reason to believe that P3
should be any different.
Tom D why are we at 3 bucks. Basically this company is a well kept secret.
There are Oncologist that don't know about Onconase, I know that for a fact.
There are many institutions that don't know about Alfacell.
Plus at this stage of the game, why invest at $3 not knowing the data when you can wait
a few more months and see what the results are, and invest with much less risk.
It is the same with an agreement, any large company will wait to get the data results before
signing an agreement, and if the data is good we are in a stronger position
in the negotiations.
If I were confident about the data, I would be silent myself.
This is just my opinion. 2 more months will tell the story, at that point we will know
who is right and who is wrong.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext